Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis
-
Mira Barak
Abstract
There are two fully automated high-throughput clinical instruments for brain natriuretic peptide (BNP) assays, the Bayer ADVIA Centaur assay, and the Abbott AxSYM assay. Although both recommend a cut-off value of 100pg/mL, we are unaware of previous studies that have compared the unadjusted results of the two methods, required for proper evaluation of patients undergoing this test on different platforms. From 43 hemodialysis patients, 80 paired samples were collected by venipuncture into plastic evacuated tubes containing EDTA. The Bayer assay yielded lower values than the Abbott assay, with linear regression of 0.53×Abbott assay (95% confidence interval, 0.50–0.56) being forced through 0, demonstrating an r 2-value of 0.954. Regression for the Abbott assay was 1.79×Bayer assay (95% CI, 1.69–1.89). The cut-off values for abnormal BNP results analyzed on the Abbott system are not identical to those on the Bayer system, and this needs to be taken into account when comparing studies on the clinical utility of these systems.
References
1 Wu AH, Packer M, Smith A, Bijou R, Fink K, Mair J, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated b-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004; 50: 867–73. 10.1373/clinchem.2003.026138Search in Google Scholar PubMed
2 Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Preliminary evaluation of the AxSYM b-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin Chem 2004; 50: 1104–6. 10.1373/clinchem.2004.031484Search in Google Scholar PubMed
3 Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides b-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071–4. 10.1373/clinchem.2003.030692Search in Google Scholar PubMed
4 Bayer HealthCare LLC. ADVIA Centaur BNP package insert. Terrytown, NY, USA: Bayer HealthCare LLC, Diagnostic Division, 2003. Search in Google Scholar
5 Abbott Diagnostics Division. Abbott AxSYM BNP system package insert. Wiesbaden, Germany: Axis-Shield Diagnostics, Abbott Diagnostics Division, 2003. Search in Google Scholar
6 Vogeser M, Jacob K. B-type natriuretic peptide (BNP): validation of an immediate response assay. Clin Lab 2001; 47: 29–33. Search in Google Scholar
7 Jortani SA, Prabhu SD, Valdes R. Strategies for developing biomarkers of heart failure. Clin Chem 2004; 50: 265–78. 10.1373/clinchem.2003.027557Search in Google Scholar PubMed
8 Clerico A. The increasing impact of laboratory medicine on clinical cardiology. Clin Chem Lab Med 2003; 41: 871–83. 10.1515/CCLM.2003.132Search in Google Scholar PubMed
9 Wang TJ, Larson MG, Level D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–63. 10.1056/NEJMoa031994Search in Google Scholar PubMed
10 Mueller C, Scholer A, Lauie-Kilian K, Marina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647–54. 10.1056/NEJMoa031681Search in Google Scholar PubMed
11 Goto T, Takase H, Toriyama T, Sugiura T, Kurita Y, Tsuru N, et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002; 92: 610–5. 10.1159/000064100Search in Google Scholar PubMed
12 Nitta K, Kawashima A, Yumura W, Naruse M, Oba T, Kabaya T, et al. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol 1998; 18: 411–5. 10.1159/000013385Search in Google Scholar PubMed
13 Osajima A, Okazaki M, Kato H, Anai H, Tsuda Y, Segawa K, et al. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 2001; 21: 112–9. 10.1159/000046233Search in Google Scholar PubMed
14 Naganuma T, Sugimura K, Wada S, Yasumoto R, Sugimura T, Masuda C, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22: 437–44. 10.1159/000065272Search in Google Scholar PubMed
© by Walter de Gruyter Berlin New York
Articles in the same Issue
- Second Santorini Conference “From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment”
- Expressed genome molecular signatures of heart failure
- Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice
- Alcohol and gene interactions
- β-Carotene stimulates chemotaxis of human endothelial progenitor cells
- Effect of interferon-γ, interleukin-10, lipopolysaccharide and tumor necrosis factor-α on chitotriosidase synthesis in human macrophages
- Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients
- Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography
- Both core and terminal glycosylation alter epitope expression in thyrotropin and introduce discordances in hormone measurements
- Do we measure bilirubin correctly anno 2005?
- Differences in mortality on the basis of laboratory parameters in an unselected population at the Emergency Department
- An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man™ probes
- A reference material for traceability of aspartate aminotransferase (AST) results
- Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis
- Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma
- Guidelines for sampling, measuring and reporting ionized magnesium in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing
- Evaluation of the Quantase™ neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis
Articles in the same Issue
- Second Santorini Conference “From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment”
- Expressed genome molecular signatures of heart failure
- Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice
- Alcohol and gene interactions
- β-Carotene stimulates chemotaxis of human endothelial progenitor cells
- Effect of interferon-γ, interleukin-10, lipopolysaccharide and tumor necrosis factor-α on chitotriosidase synthesis in human macrophages
- Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients
- Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography
- Both core and terminal glycosylation alter epitope expression in thyrotropin and introduce discordances in hormone measurements
- Do we measure bilirubin correctly anno 2005?
- Differences in mortality on the basis of laboratory parameters in an unselected population at the Emergency Department
- An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man™ probes
- A reference material for traceability of aspartate aminotransferase (AST) results
- Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis
- Multicenter evaluation of the analytical and clinical performance of the Elecsys ® S100 immunoassay in patients with malignant melanoma
- Guidelines for sampling, measuring and reporting ionized magnesium in undiluted serum, plasma or blood: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division, Committee on Point of Care Testing
- Evaluation of the Quantase™ neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis
